Camrelizumab and SBRT
CART0326
Phase 2 other active
Quick answer
Camrelizumab and SBRT for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active